Drug Profile
Inecalcitol - ATON
Alternative Names: TX-522Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Ghent University; Katholieke Universiteit Leuven
- Developer ATON
- Class Alkynes; Antipsoriatics; Secosteroids; Small molecules; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Multiple myeloma; Prostate cancer; Psoriasis